Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial